Emerging Vaccines | Disease Landscape & Forecast | G7 | 2022
Vaccination programs have had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life to prevent infections and diseases associated with long-term chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, other vaccines are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options. This content will include coverage of current and emerging vaccines for key infectious diseases such as HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19. This content will also assess the impact of the COVID-19 pandemic on the vaccines market.
Questions answered
- What are the sizes of the populations eligible for key vaccination programs in the G7?
- Who are the key decision makers for vaccine purchasing and administration, and how does this group vary by geography?
- What are the key drivers of brand preference in a given vaccine market?
- Which pathogens are associated with the most unmet need in terms of the development of a new or improved vaccine? Which patient pools do experts anticipate will be eligible for these vaccines?
- How will the current vaccines pipeline fulfill areas of unmet need in this market?
- How will key current and emerging vaccines perform commercially?
- How has the COVID-19 pandemic impacted the use of current vaccines?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, EU5, Japan
Primary research: Approximately 16 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed events of emerging vaccines by country, segmented by key infectious diseases (HPV, HZ, meningococcus, pneumococcus, seasonal influenza, HBV, RSV, COVID-19).
Forecast: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2031, segmented by vaccine, geography, and key indications.
Emerging therapies: Registered / preregistered: 5+; Phase III: 12+; Phase II: 20+
